These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
147 related items for PubMed ID: 10847253
1. Indications for hospitalization of patients with hyperkalemia. Charytan D, Goldfarb DS. Arch Intern Med; 2000 Jun 12; 160(11):1605-11. PubMed ID: 10847253 [Abstract] [Full Text] [Related]
2. Trimethoprim-sulfamethoxazole therapy in outpatients: is hyperkalemia a significant problem? Alappan R, Buller GK, Perazella MA. Am J Nephrol; 1999 Jun 12; 19(3):389-94. PubMed ID: 10393376 [Abstract] [Full Text] [Related]
3. [Influence of hyperkalemia on clinical decision making]. Matsuo S, Yamamoto Y, Asano H, Takahashi H. Rinsho Byori; 1996 Nov 12; 44(11):1087-92. PubMed ID: 8953941 [Abstract] [Full Text] [Related]
4. Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole. Alappan R, Perazella MA, Buller GK. Ann Intern Med; 1996 Feb 01; 124(3):316-20. PubMed ID: 8554227 [Abstract] [Full Text] [Related]
5. Effects of presentation and electrocardiogram on time to treatment of hyperkalemia. Freeman K, Feldman JA, Mitchell P, Donovan J, Dyer KS, Eliseo L, White LF, Temin ES. Acad Emerg Med; 2008 Mar 01; 15(3):239-49. PubMed ID: 18304054 [Abstract] [Full Text] [Related]
6. Severe hyperkalemia requiring hospitalization: predictors of mortality. An JN, Lee JP, Jeon HJ, Kim DH, Oh YK, Kim YS, Lim CS. Crit Care; 2012 Nov 21; 16(6):R225. PubMed ID: 23171442 [Abstract] [Full Text] [Related]
7. The use of sodium polystyrene sulfonate in the inpatient management of hyperkalemia. Kessler C, Ng J, Valdez K, Xie H, Geiger B. J Hosp Med; 2011 Mar 21; 6(3):136-40. PubMed ID: 21387549 [Abstract] [Full Text] [Related]
8. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). Eschalier R, McMurray JJ, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ, Shi H, Vincent J, Rossignol P, Zannad F, Pitt B, EMPHASIS-HF Investigators. J Am Coll Cardiol; 2013 Oct 22; 62(17):1585-93. PubMed ID: 23810881 [Abstract] [Full Text] [Related]
9. Hyperkalemia in hospitalized patients: causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines. Acker CG, Johnson JP, Palevsky PM, Greenberg A. Arch Intern Med; 1998 Apr 27; 158(8):917-24. PubMed ID: 9570179 [Abstract] [Full Text] [Related]
10. Life-threatening drug-associated hyperkalemia: a retrospective study from laboratory signals. Noize P, Bagheri H, Durrieu G, Haramburu F, Moore N, Giraud P, Galinier M, Pourrat J, Montastruc JL. Pharmacoepidemiol Drug Saf; 2011 Jul 27; 20(7):747-53. PubMed ID: 21438068 [Abstract] [Full Text] [Related]
11. Development and outcomes of hyperkalemia in hospitalized patients: potential implications for care. Wetmore JB, Yan H, Peng Y, Gilbertson DT, Herzog CA. Am Heart J; 2021 Nov 27; 241():59-67. PubMed ID: 34293294 [Abstract] [Full Text] [Related]
12. Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial). Khan SS, Campia U, Chioncel O, Zannad F, Rossignol P, Maggioni AP, Swedberg K, Konstam MA, Senni M, Nodari S, Vaduganathan M, Subacius H, Butler J, Gheorghiade M, EVEREST Trial Investigators. Am J Cardiol; 2015 Mar 15; 115(6):790-6. PubMed ID: 25728846 [Abstract] [Full Text] [Related]
13. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? Reardon LC, Macpherson DS. Arch Intern Med; 1998 Jan 12; 158(1):26-32. PubMed ID: 9437375 [Abstract] [Full Text] [Related]
14. Co-trimoxazole induced hyperkalemia and potassium monitoring in hospitalized patients. Plantaz MMEA, Veldman BAJ, Esselink AC, Fleuren HWHA, Kramers C. Int J Clin Pharm; 2020 Dec 12; 42(6):1405-1411. PubMed ID: 33025449 [Abstract] [Full Text] [Related]
15. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial. Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, Stasiv Y, Zawadzki R, Berman L, Bushinsky DA, AMETHYST-DN Investigators. JAMA; 2015 Jul 14; 314(2):151-61. PubMed ID: 26172895 [Abstract] [Full Text] [Related]
16. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial. Heerspink HJ, Gao P, de Zeeuw D, Clase C, Dagenais GR, Sleight P, Lonn E, Teo KT, Yusuf S, Mann JF. Eur J Prev Cardiol; 2014 Mar 14; 21(3):299-309. PubMed ID: 24191305 [Abstract] [Full Text] [Related]
17. [Life threatening hyperkalemia: the value of the electrocardiogram]. Trof RJ, Brouwer RM. Ned Tijdschr Geneeskd; 2004 May 15; 148(20):969-75. PubMed ID: 15181720 [Abstract] [Full Text] [Related]
19. Clinical and metabolic features of thyrotoxic periodic paralysis in 24 episodes. Manoukian MA, Foote JA, Crapo LM. Arch Intern Med; 1999 Mar 22; 159(6):601-6. PubMed ID: 10090117 [Abstract] [Full Text] [Related]
20. Incidence of and risk factors for newly diagnosed hyperkalemia after hospital discharge in non-dialysis-dependent CKD patients treated with RAS inhibitors. Saito Y, Yamamoto H, Nakajima H, Takahashi O, Komatsu Y. PLoS One; 2017 Mar 22; 12(9):e0184402. PubMed ID: 28877239 [Abstract] [Full Text] [Related] Page: [Next] [New Search]